1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

  • February 2016
  • 88 pages
  • La Merie Publishing
Report ID: 3605802

Summary

Table of Contents

Search Inside

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists


Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but „difficult-to-drug“ target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter. 


The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concers for novel RORgamma modulators were identified. Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.


The report provides an understanding of:



  • The target RORgamma

  • Clinical and non-clinical target validation

  • Clinical lead and up-side indications

  • Drug discovery strategies and technologies

  • Commercial value of drug discovery collaborations

  • R&D timelines from start of screening to first-in-human studies

  • Competitive landscape of RORgamma antagonists

  • Agonists of RORgamma for cancer

  • Profiles of unpartnered technology companies and lead projects

  • R&D Partnerships and their discovery approaches and lead molecules

  • Unpartnered pharmaceutical companies and their programs


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast – 2025

  • $ 5750
  • Industry report
  • July 2017
  • by Delve Insight

DelveInsight’s “Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast – 2025” Reports provides an overview of the disease and global market size of the Interstitial Cystitis ...

Global Therapeutic Vaccines Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global therapeutic vaccines market was valued at USD 11 billion in 2015 and is projected to reach USD 51 billion by 2021, at a CAGR of 29% during the forecast period. The increasing prevalence of chronic ...

Rheumatoid - Inflammatory Diseases Markers Tests - Medical Devices Pipeline Assessment, 2017

  • $ 4000
  • Industry report
  • September 2017
  • by GlobalData

Rheumatoid - Inflammatory Diseases Markers Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData’s Medical Devices sector report, “Rheumatoid - Inflammatory Diseases Markers Tests - ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Germany

  • September 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

Cancer Statistics in the US - Forecast

  • September 2017
    3 pages
  • Hospital  

    Blood Disease  

  • United States  

    Europe  

View report >

Autoimmune Disease Statistics in the US

  • September 2017
    9 pages
  • Autoimmune Dise...  

    Hospital  

  • United States  

View report >

Related Market Segments :

Autoimmune Disease
Pharmaceutical

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.